Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-palmitoyl-2-oleoyl-3-arachidonoyl-rac-glycerol (C57H100O6) is a specific triacylglycerol identified as a key protective mediator in the arachidonate 15-lipoxygenase (ALOX15) pathway within lung endothelial cells. Research presented at AHA 2025 demonstrates that this lipid is naturally induced during innocuous lung thrombosis and serves to inhibit lung endothelial apoptosis and mitigate inflammatory responses. In preclinical studies, exogenous delivery of this lipid reversed sepsis-induced acute lung injury (ALI) and inflammation in ALOX15-deficient mice. It is currently being investigated by researchers at the University of South Carolina and Northwestern University as a novel therapeutic approach for treating acute respiratory distress syndrome (ARDS) and other forms of inflammatory lung injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-palmitoyl-2-oleoyl-3-arachidonoyl-rac-glycerol.